HIA
SRPT icon

HFM Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

HFM Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$17 – 1311
2025
Q2 		$17 Buy
+1
New +$43 ﹤0.01% 1273

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HFM Investment Advisors's SRPT Position: Q3 2025 in Review

HFM Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 1 share — an estimated $17 sold.

HFM Investment Advisors first reported a position in SRPT in Q2 2025 and held it in 1 quarter. The position peaked at $17 in Q2 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • HFM Investment Advisors reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HFM Investment Advisors sold 1 Sarepta Therapeutics share in Q3 2025, an estimated $17.
  • HFM Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 1 quarter.
  • HFM Investment Advisors's Sarepta Therapeutics position peaked at $17 in Q2 2025.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on HFM Investment Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.